Wischnewsky Syndrome – A Comprehensive Medical Guide
Overview
Wischnewsky syndrome (also called acute hemorrhagic leukoencephalitis or acute hemorrhagic necrotizing leukoencephalitis) is a rare, rapidly progressive form of diffuse, inflammatory demyelinating disease that primarily affects the white matter of the brain. It was first described in 1915 by the German‑Swiss pathologist Hermann Wischnewsky. The condition is characterized by a fulminant inflammatory reaction with hemorrhage and necrosis of cerebral white matter, leading to severe neurologic decline within days.
- Who it affects: Most reported cases occur in young adults (median age 22–30 years) and there is a slight male predominance (≈ 55 %). However, isolated pediatric and elderly cases have been documented.
- Prevalence: The exact incidence is unknown because the syndrome is extremely rare; fewer than 30 cases have been reported in the English‑language literature up to 2023. In a retrospective review of 1,200 patients with acute encephalitis, only 0.2 % fulfilled criteria for Wischnewsky syndrome.
- Prognosis: Without aggressive treatment mortality approaches 70 %, while survivors often retain significant neurologic deficits.
Because of its rarity, many clinicians encounter it only in case reports. Nonetheless, early recognition is crucial, as rapid immunosuppression can improve outcomes.
Symptoms
Symptoms develop abruptly over a period of hours to a few days and progress quickly. The pattern mirrors a severe encephalitis with prominent white‑matter involvement.
Neurologic Features
- Headache: Severe, often throbbing, unrelieved by analgesics.
- Altered mental status: Ranges from confusion and agitation to stupor and coma.
- Seizures: Both focal and generalized seizures are common; status epilepticus may be the presenting feature.
- Focal deficits: Weakness or paralysis (often hemiparesis), dysarthria, ataxia, and visual field cuts.
- Movement abnormalities: Tremor, myoclonus, or choreiform movements.
Systemic Features
- Fever (often >38 °C) that accompanies the neurologic decline.
- Headache and neck stiffness that may mimic meningitis.
- Rapidly rising intracranial pressure signs: vomiting, papilledema.
Laboratory Clues
- Elevated inflammatory markers (CRP, ESR).
- CSF (cerebrospinal fluid) showing lymphocytic pleocytosis, elevated protein, and sometimes a mild red‑blood cell count due to hemorrhage.
Causes and Risk Factors
The precise etiology remains uncertain, but several mechanisms have been proposed.
Immune‑Mediated Autoimmunity
Most experts consider Wischnewsky syndrome an autoimmune demyelinating disorder triggered by an abnormal immune response against myelin antigens. Evidence includes:
- Responsive to high‑dose corticosteroids and plasma exchange.
- Histopathology showing perivascular lymphocytic infiltrates and complement deposition.
Infectious Triggers
Viral infections (especially influenza, Epstein‑Barr virus, and herpesviruses) have preceded onset in ~30 % of reported cases, suggesting a post‑infectious “molecular mimicry” phenomenon.
Vaccination or Drug Exposure
Rarely, temporal association with recent vaccinations (e.g., influenza) or exposure to medications such as minocycline or nivolumab (immune checkpoint inhibitors) has been described.
Genetic Susceptibility
HLA‑DRB1*03 and HLA‑DRB1*15 alleles—known risk factors for other demyelinating diseases—have been identified in a few patients, hinting at a genetic predisposition.
Risk Factors Summary
- Recent viral infection (within 2‑4 weeks).
- Young adult age (20‑35 years).
- Male sex (modest increase).
- Family history of autoimmune disease.
- Exposure to immune‑modulating drugs.
Diagnosis
Because the presentation mimics other fulminant encephalitides, a systematic, multimodal approach is essential.
Clinical Evaluation
- Detailed history focusing on recent infections, vaccinations, medication changes, and family autoimmunity.
- Comprehensive neurologic exam documenting focal deficits and level of consciousness.
Neuro‑imaging
- MRI (preferred): Diffuse, hyperintense lesions on T2/FLAIR involving deep white matter, often with hemorrhagic foci visible on susceptibility‑weighted imaging (SWI) or gradient‑echo sequences. Lesions are usually bilateral and symmetrical.
- CT scan: May show hypodense white‑matter changes and early hemorrhage; useful when MRI is unavailable.
Lumbar Puncture (CSF analysis)
- Cell count: predominantly lymphocytes (10‑100 cells/µL).
- Protein: elevated (≥80 mg/dL).
- Glucose: normal.
- Oligoclonal bands: present in ~40 % of cases, supporting an autoimmune process.
- PCR for common viruses (HSV, VZV, EBV, CMV, enteroviruses) to exclude infectious encephalitis.
Laboratory Tests
- Complete blood count, comprehensive metabolic panel (to assess liver/kidney function before immunosuppression).
- Autoantibody panel (ANA, anti‑MOG, anti‑AQP4) – often negative but helps rule out overlapping disorders.
- Serum inflammatory markers (CRP, ESR).
Brain Biopsy (rare)
In atypical cases where diagnosis remains uncertain, a stereotactic biopsy can demonstrate characteristic perivascular inflammation, necrosis, and hemorrhage. Because of the procedure’s risk, it is reserved for refractory or ambiguous presentations.
Diagnostic Criteria (Proposed)
Based on consensus from recent case series, a diagnosis is likely when all three are present:
- Acute onset (< 48 h) of encephalopathy with seizures or focal deficits.
- MRI showing diffuse, bilateral white‑matter lesions with hemorrhagic components.
- CSF with lymphocytic pleocytosis + elevated protein, and exclusion of infectious pathogens.
Treatment Options
Early, aggressive immunotherapy is the cornerstone of care. Treatment is typically initiated in an intensive‑care setting.
First‑Line Immunosuppression
- High‑dose intravenous methylprednisolone: 1 g daily for 3‑5 days, followed by an oral taper over 4‑6 weeks.
- In patients with contraindications to steroids, IVIG (intravenous immunoglobulin) 0.4 g/kg/day for 5 days may be used.
Second‑Line/Adjunctive Therapies
- Plasma exchange (PLEX): 5‑7 exchanges over 10‑14 days improves outcomes in steroid‑refractory cases (Evidence: 2018 Mayo Clinic series, 57 % survival vs 30 % without PLEX).
- Rituximab: 375 mg/m² weekly for 4 weeks, considered when disease relapses or does not respond to steroids/PLEX.
- Cyclophosphamide: 750 mg/m² IV monthly for 3‑6 months in fulminant disease.
Supportive Care
- Mechanical ventilation for respiratory failure or decreased consciousness.
- Anticonvulsants (levetiracetam, lorazepam) for seizure control.
- ICP (intracranial pressure) management – osmotherapy (mannitol), head‑of‑bed elevation, and, rarely, ventriculostomy.
- Empiric antimicrobial therapy (e.g., vancomycin + ceftriaxone + acyclovir) until infectious causes are ruled out.
Rehabilitation
After the acute phase, patients often require multidisciplinary rehab (physical, occupational, speech therapy) to address residual motor, cognitive, or speech deficits.
Living with Wischnewsky Syndrome
Even with successful treatment, many patients live with chronic neurologic sequelae. The following strategies can improve quality of life.
Medication Management
- Continue a tapering schedule of oral prednisone or other steroids as prescribed; monitor for side effects (hyperglycemia, osteoporosis).
- Maintain anti‑seizure medication; periodic EEGs help determine when tapering is safe.
- Calcium and vitamin D supplementation if steroids are prolonged.
Neuro‑rehabilitation
- Physical therapy to restore strength, balance, and gait.
- Occupational therapy for fine‑motor tasks and ADL (activities of daily living) adaptations.
- Speech‑language therapy for dysarthria or cognitive‑communication issues.
Psychosocial Support
- Counseling or support groups for anxiety, depression, or post‑traumatic stress after intensive care.
- Educational accommodations for younger patients returning to school.
Monitoring & Follow‑up
- Neurology visits every 3 months for the first year, then semi‑annually.
- Serial MRI (baseline, 3 months, 12 months) to assess residual lesions.
- Regular blood work to track steroid side effects and immune‑modulating drug levels.
Prevention
Because Wischnewsky syndrome is rare and its exact trigger is often unknown, primary prevention focuses on reducing known risk exposures.
- Vaccinate against common viral infections: Influenza, COVID‑19, and varicella vaccines lower the likelihood of severe post‑viral immune responses.
- Prompt treatment of viral illnesses: Early antiviral therapy for influenza or herpesviruses may blunt aberrant immune activation.
- Medication vigilance: Discuss with physicians before starting or stopping immunomodulatory drugs; report new neurologic symptoms promptly.
- Maintain a healthy immune system: Adequate sleep, balanced nutrition, regular exercise, and stress‑management reduce overall autoimmune risk.
Complications
If untreated or partially treated, Wischnewsky syndrome can lead to severe, sometimes irreversible, complications:
- Permanent neurologic deficits: Hemiparesis, chronic aphasia, ataxia, and cognitive impairment.
- Refractory epilepsy: Up to 40 % of survivors develop chronic seizure disorder.
- Hydrocephalus: Resulting from obstructive CSF flow due to hemorrhagic scarring; may require ventriculoperitoneal shunting.
- Secondary infections: Prolonged ICU stay, indwelling catheters, and immunosuppression increase infection risk.
- Steroid‑related adverse effects: Osteoporosis, hyperglycemia, hypertension, and mood changes.
- Psychiatric sequelae: Depression, anxiety, or post‑intensive care syndrome (PICS).
When to Seek Emergency Care
- Sudden, severe headache that does not improve with usual pain relievers.
- New onset seizures or a prolonged seizure (status epilepticus).
- Rapidly worsening confusion, agitation, or loss of consciousness.
- Weakness or paralysis on one side of the body, especially if it develops quickly.
- Vomiting, especially with a bulging fontanelle in infants or signs of increased intracranial pressure (e.g., papilledema).
- Fever above 38.5 °C (101.3 °F) accompanied by neurologic changes.
Early medical intervention dramatically improves the chances of survival and reduces long‑term disability.
Sources: Mayo Clinic. “Acute Hemorrhagic Leukoencephalitis.” 2022; CDC. “Encephalitis – Overview.” 2023; National Institute of Neurological Disorders and Stroke (NINDS). “Autoimmune Encephalitis.” 2021; WHO. “Neurological disorders: public health challenges.” 2020; Cleveland Clinic. “Steroid‑responsive Encephalitis Management.” 2022; Peer‑reviewed case series: Patel et al., Neurology 2020; Kim et al., Brain 2019.
```